10-QPeriod: Q1 FY2022

Merck & Co., Inc. Quarterly Report for Q1 Ended Mar 31, 2022

Filed May 5, 2022For Securities:MRK

Summary

Merck & Co., Inc. reported strong financial results for the first quarter ended March 31, 2022, with total sales increasing by a significant 50% year-over-year to $15.9 billion. This growth was primarily driven by substantial sales of Lagevrio, its COVID-19 antiviral treatment, which generated $3.2 billion in revenue. Keytruda, the company's flagship oncology drug, also demonstrated robust performance with a 23% increase in sales, alongside strong contributions from its vaccine portfolio, notably Gardasil and Gardasil 9. Despite the overall positive financial performance, the company's gross margin saw a decline due to the lower margin profile of Lagevrio and increased manufacturing costs. The company also reported a substantial increase in Research and Development expenses, indicating continued investment in its pipeline. Looking ahead, Merck anticipates lower Lagevrio sales in subsequent quarters and faces upcoming patent expirations for key diabetes medications like Januvia and Janumet, which will likely impact future revenue streams. The company also continues to navigate ongoing legal proceedings and is closely monitoring the geopolitical situation in Ukraine.

Financial Highlights

51 data points
Beta

Revenue

$15.90B

66.2% Gross Margin

Net Income

$4.31B

27.1% Net Margin

EPS (Diluted)

$1.70

Total Assets

$106.67B

Cash & Equivalents

$8.61B

Free Cash Flow

$4.76B

Financial Statements
Beta
Revenue$15.90B
Cost of Revenue$5.38B
Gross Profit$10.52B
R&D Expenses$2.58B
SG&A Expenses$2.32B
Operating Income$4.31B
Interest Expense$243.00M
Net Income$4.31B
EPS (Basic)$1.70
EPS (Diluted)$1.70
Shares Outstanding (Basic)2.53B
Shares Outstanding (Diluted)2.54B

Key Highlights

  • 1Total sales surged 50% year-over-year to $15.9 billion, driven by strong performance across multiple therapeutic areas.
  • 2Lagevrio, Merck's COVID-19 antiviral, was a major revenue contributor, generating $3.2 billion in sales.
  • 3Keytruda, the oncology blockbuster, showed continued strength with a 23% increase in sales, supported by new indications and global uptake.
  • 4The vaccine segment, particularly Gardasil and Gardasil 9, experienced significant growth, up 59%.
  • 5Gross margin decreased to 66.2% from 69.9% in the prior year, primarily due to the inclusion of Lagevrio sales and higher manufacturing costs.
  • 6Research and Development expenses increased by 7% to $2.58 billion, reflecting ongoing investment in the company's pipeline.
  • 7Merck anticipates lower sales for Lagevrio in the remaining quarters of 2022, projecting full-year sales between $5.0 billion and $5.5 billion.

Frequently Asked Questions

The primary driver of Merck's sales growth in the first quarter of 2022 was the substantial sales of Lagevrio (molnupiravir), its COVID-19 antiviral treatment, which generated $3.2 billion in revenue. Strong performance from Keytruda, its oncology drug, and growth in its vaccine portfolio also contributed significantly.

Merck anticipates that sales of Lagevrio in each of the remaining quarters of 2022 will be lower than the first quarter's sales. The company projects full-year 2022 Lagevrio sales to be between $5.0 billion and $5.5 billion.

Merck faces several key challenges. These include upcoming patent expirations for its diabetes medications Januvia and Janumet, which are expected to lead to substantial sales declines post-exclusivity. The company is also subject to ongoing litigation, and the geopolitical situation in Ukraine could have unpredictable impacts. Additionally, pricing pressures in healthcare markets worldwide continue to exert influence on sales performance.